Mutual of America Capital Management LLC Takes $940,000 Position in Immunocore Holdings plc (NASDAQ:IMCR)

Mutual of America Capital Management LLC acquired a new stake in Immunocore Holdings plc (NASDAQ:IMCR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 13,754 shares of the company’s stock, valued at approximately $940,000.

Several other institutional investors have also modified their holdings of IMCR. IFP Advisors Inc lifted its stake in shares of Immunocore by 32.9% in the 3rd quarter. IFP Advisors Inc now owns 2,397 shares of the company’s stock valued at $124,000 after purchasing an additional 594 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Immunocore during the 3rd quarter worth approximately $650,000. TD Asset Management Inc lifted its stake in shares of Immunocore by 109.9% during the 3rd quarter. TD Asset Management Inc now owns 301,920 shares of the company’s stock worth $15,670,000 after acquiring an additional 158,086 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Immunocore by 54.9% during the 3rd quarter. Assetmark Inc. now owns 11,011 shares of the company’s stock worth $571,000 after acquiring an additional 3,902 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Immunocore by 1.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company’s stock worth $5,639,000 after acquiring an additional 1,513 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Trading Up 0.3 %

Shares of NASDAQ:IMCR opened at $55.82 on Tuesday. Immunocore Holdings plc has a 12-month low of $42.21 and a 12-month high of $76.98. The business’s fifty day simple moving average is $63.38 and its 200-day simple moving average is $60.54. The company has a market capitalization of $2.78 billion, a PE ratio of -48.12 and a beta of 0.89. The company has a current ratio of 3.80, a quick ratio of 3.77 and a debt-to-equity ratio of 0.13.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The company had revenue of $70.16 million during the quarter, compared to analysts’ expectations of $53.25 million. During the same quarter in the prior year, the business posted ($0.63) earnings per share. The company’s revenue was up 22.4% compared to the same quarter last year. As a group, equities research analysts predict that Immunocore Holdings plc will post -1.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IMCR shares. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Immunocore in a research note on Wednesday, March 6th. JPMorgan Chase & Co. raised their price target on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Oppenheimer reissued an “outperform” rating and set a $87.00 price target (up from $85.00) on shares of Immunocore in a research note on Thursday, February 29th. Canaccord Genuity Group raised their price objective on Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a report on Thursday, February 29th. Finally, Mizuho raised their price objective on Immunocore from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $80.55.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.